Thus, immunotherapy efficacy is compromised in cold HNSCC tumours with an objective response rate of single-agent anti-PD-1/PD-L1 immunotherapy as low as 13–14% in patients with HNSCC who are not screened for immune checkpoint expression prior to treatment [12, 68, 69]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.